chevron_leftBack
As of 13 June 2026, vTv Therapeutics Inc. has a market cap of $129.06M USD, ranking #23828 globally and #3742 in the United States.
It ranks #2138 in the Healthcare sector, and #775 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$129.06MUSD
Enterprise Value
$287.45MUSD
EBITDA (TTM)
-$32.79MUSD
Net Income (TTM)
-$26.97MUSD
PB Ratio
6.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Paul Sekhri
open_in_new
Employees
26
Founded
2015
IPO
30 Jul 2015
Website
vtvtherapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.2% | -23% | -19% | -8.2% | 50% | 35% |
News
Loading...
VTVT Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
VTVT
vTv Therapeutics Inc Class A
ISIN: US9183852048
Shares Out.:
Shares Outstanding:
3.939M1
Shares Float:
2.044M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
31.26 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About vTv Therapeutics Inc.
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
590K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
424K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
279K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
212K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
116K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
91K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
249K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
224K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
213K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
141K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
85K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
84K%
80.96B GBP
|
14.6
|
chevron_leftBack